Show simple item record

dc.contributor.authorAmeratunga, Men_US
dc.contributor.authorColeman, Nen_US
dc.contributor.authorWelsh, Len_US
dc.contributor.authorSaran, Fen_US
dc.contributor.authorLopez, Jen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2018-06-21T09:50:58Z
dc.date.issued2018-04-27en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29854316en_US
dc.identifier24896en_US
dc.identifier.citationOncotarget, 2018, 9 (32), pp. 22802 - 22816en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1893
dc.identifier.eissn1949-2553en_US
dc.identifier.doi10.18632/oncotarget.24896en_US
dc.description.abstractImmunotherapeutics have revolutionized the management of solid malignancies over the last few years. Nevertheless, despite relative successes of checkpoint inhibitors in numerous solid tumour types, success in tumours of the central nervous system (CNS) has been lacking. There are several possible reasons for the relative lack of success of immunotherapeutics in this setting, including the immune microenvironment of glioblastoma, lymphocyte tracking through the blood-brain barrier (BBB) into the central nervous system and impairment of drug delivery into the CNS through the BBB. This review utilizes the cancer-immunity cycle as a conceptual framework through which the specific challenges associated with the development of immunotherapeutics for CNS malignancies can be viewed.en_US
dc.format.extent22802 - 22816en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectcancer-immunity cycleen_US
dc.subjectcheckpoint inhibitorsen_US
dc.subjectclinical trialsen_US
dc.subjectglioblastomaen_US
dc.subjectimmunotherapyen_US
dc.titleCNS cancer immunity cycle and strategies to target this for glioblastoma.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-03-11en_US
rioxxterms.versionofrecord10.18632/oncotarget.24896en_US
rioxxterms.licenseref.startdate2018-04-27en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfOncotargeten_US
pubs.issue32en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.publication-statusPublished onlineen_US
pubs.volume9en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMedicine (de Bono Prostate)en_US
dc.contributor.icrauthorLopez, Juanitaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/